Breakthrough helps develop novel painkillers

February 11, 2010 05:55 pm | Updated 05:55 pm IST - Washington

A young woman holds her neck in pain. New research claims breakthrough in pain medication.

A young woman holds her neck in pain. New research claims breakthrough in pain medication.

A breakthrough has opened the door for the development of a new category of painkillers which may be effective in treating pain related to a number of conditions including cancer, AIDS, migraines and diabetes.

The painkillers, called TRPV1 antagonists, can be activated by pepper like chemicals and high temperatures.

These drugs block the TRPV1 channel, which is the same receptor responsible for the sensation of hotness from hot peppers.

However, clinical trials have revealed that TRPV1 antagonists cause hyperthermia, which is a dangerous, fever-like rise in body temperature.

The same channel is responsible for pain caused by these diverse stimuli. For a number of years, scientists have focussed on the development of TRPV1 antagonists, but have been stymied by the dangerous hyperthermia side-effect.

The ground breaking project to eliminate the side-effect was led by Andrej A. Romanovsky at Barrow Neurological Institute at St. Joseph's Hospital and Medical Centre in Arizona and included researchers from Arizona State University.

“We think we have found a recipe for making TRPV1 antagonists that do not have this fever-like side effect,” says Romanovsky.

These findings were published in the Journal of Neuroscience.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.